Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia

Journal of Lipid Research

Volumn 53, Issue 1, 2012, Pages 51-65

  Yin, Wu ^a   Carballo Jane, Ester ^a   McLaren, David G ^a   Mendoza, Vivienne H ^a   Gagen, Karen ^a   Geoghagen, Neil S ^a   McNamara, Lesley Ann ^a   Gorski, Judith N ^a   Eiermann, George J ^a   Petrov, Aleksandr ^a   Wolff, Michael ^a   Tong, Xinchun ^a   Wilsie, Larissa C ^a   Akiyama, Taro E ^a   Chen, Jing ^a   Thankappan, Anil ^a   Xue, Jiyan ^a   Ping, Xiaoli ^a   Andrews, Genevieve ^a   Wickham, L Alexandra ^a   Gai, Cesaire L ^a   Trinh, Tu ^a   Kulick, Alison A ^a   Donnelly, Marcie J ^a   Voronin, Gregory O ^a   Rosa, Ray ^a   Cumiskey, Anne Marie ^a   Bekkari, Kavitha ^a   Mitnaul, Lyndon J ^a   Puig, Oscar ^a   Chen, Fabian ^a   Raubertas, Richard ^a   Wong, Peggy H ^a   Hansen, Barbara C ^b   Koblan, Ken S ^b,c   Roddy, Thomas P ^a   Hubbard, Brian K ^a   Strack, Alison M ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Cholesterol; Lipidomic; Low density lipoprotein; Preclinical animal models; Statins

Indexed keywords

C REACTIVE PROTEIN; DIACYLGLYCEROL; FATTY ACID; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CHLOROCEBUS; CONTROLLED STUDY; DISEASE MODEL; DOG; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FAST PROTEIN LIQUID CHROMATOGRAPHY; HAMSTER; HUMAN; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RABBIT; RAT; RHESUS MONKEY; SPECIES DIFFERENCE; SWINE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CRICETINAE; DISEASE MODELS, ANIMAL; DOGS; DYSLIPIDEMIAS; FATTY ACIDS; HUMANS; LIPIDS; MICE; PRIMATES; SIMVASTATIN; TRIGLYCERIDES;

EID: 84455172925     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M019927     Document Type: Article

References (68)

1. Yusuf, S., S. Reddy, S. Ounpuu, and S. Anand. 2001. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 104: 2746-2753. (Pubitemid 33108145)
2. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-239. (Pubitemid 38924592)
3. Yusuf, S., S. Hawken, S. Ounpuu, T. Dans, A. Avezum, F. Lanas, M. McQueen, A. Budaj, P. Pais, J. Varigos, et al. 2004. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 364: 937-952. (Pubitemid 39208455)
4. Paramsothy, P., and R. Knopp. 2006. Management of dyslipidaemias. Heart. 92: 1529-1534. (Pubitemid 44578861)
5. Sharma, M., M. T. Ansari, A. M. Abou-Setta, K. Soares-Weiser, T. C. Ooi, M. Sears, F. Yazdi, A. Tsertsvadze, and D. Moher. 2009. Systemic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann. Intern. Med. 151: 622-630.
6. Cannon, C. P., R. P. Giugliano, M. A. Blazing, R. A. Harrington, J. L. Peterson, C. M. Sisk, J. Strony, T. A. Musliner, C. H. McCabe, E. Veltri, et al. 2008. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 156: 826-832.
7. Cannon, C. P., B. A. Steinberg, S. A. Murphy, J. L. Mega, and E. Braunwald. 2006. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. 48: 438-445. (Pubitemid 44109954)
8. Kearney, P. M., L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, and C. Baigent. 2008. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 371: 117-125.
9. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
10. Alagona, P., Jr. 2009. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am. J. Manag. Care. 15: S65-S73.
11. Kola, I. 2008. The state of innovation in drug development. Clin. Pharmacol. Ther. 83: 227-230.
12. Russell, J. C., and S. D. Proctor. 2006. Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc. Pathol. 15: 318-330. (Pubitemid 44755356)
13. Tsutsumi, K., A. Hagi, and Y. Inoue. 2001. The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol. Pharm. Bull. 24: 579-581. (Pubitemid 32499491)
14. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
15. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
16. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92: 883-893. (Pubitemid 23262411)
17. Harada, L. M., A. J. Carrilho, H. C. Oliveira, E. R. Nakandakare, and E. C. Quintao. 2006. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol. Clin. Exp. Pharmacol. Physiol. 33: 1209-1215. (Pubitemid 44923910)
18. Van Eck, M., D. Ye, R. B. Hildebrand, J. Kar Kruijt, W. de Haan, M. Hoekstra, P. C. Rensen, C. Ehnholm, M. Jauhiainen, and T. J. Van Berkel. 2007. Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice. Circ. Res. 100: 678-685. (Pubitemid 46594882)
19. Kolodgie, F. D., A. S. Katocs, Jr., E. E. Largis, S. M. Wrenn, J. F. Cornhill, E. E. Herderick, S. J. Lee, and R. Virmani. 1996. Hypercholesterolemia in the rabbit induced by feeding graded amounts of low-level cholesterol. Methodological considerations regarding individual variability in response to dietary cholesterol and development of lesion type. Arterioscler. Thromb. Vasc. Biol. 16: 1454-1464.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J. Am. Med. A ssoc. 285: 2486-2497.
21. Kontush, A., and M. J. Chapman. 2010. Lipidomics as a tool for the study of lipoprotein metabolism. Curr. Atheroscler. Rep. 12: 194-201.
22. Ekroos, K., M. Janis, K. Tarasov, R. Hurme, and R. Laaksonen. 2010. Lipidomics: a tool for studies of atherosclerosis. Curr. Atheroscler. Rep. 12: 273-281.
23. Chen, F., V. Maridakis, E. A. O'Neill, B. K. Hubbard, A. Strack, C. Beals, G. A. Herman, and P. Wong. 2011. The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia. Biomarkers. 16: 321-333.
24. Ni, Y. G., J. H. Condra, L. Orsatti, X. Shen, S. Di Marco, S. Pandit, M. J. Bottomley, L. Ruggeri, R. T. Cummings, R. M. Cubbon, et al. 2010. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285: 12882-12891.
25. Puri, P., R. A. Baillie, M. M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, C. Sargeant, M. J. Contos, and A. J. Sanyal. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46: 1081-1090. (Pubitemid 350144772)
26. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106: 3143-3421.
27. Bajpai, A., A. Goyal, and L. Sperling. 2010. Should we measure C-reactive protein on earth or just on JUPITER? Clin. Cardiol. 33: 190-198.
28. Genest, J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can. J. Cardiol. 26 (Suppl A): 41-44.
29. Claus, D. R., A. P. Osmand, and H. Gewurz. 1976. Radioimmunoassay of human C-reactive protein and levels in normal sera. J. Lab. Clin. Med. 87: 120-128.
30. Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. J. Lipid Res. 51: 3299-3305.
31. Weng, T. C., Y. H. Yang, S. J. Lin, and S. H. Tai. 2010. A systematic review and meta-analysis on the therapeutic equivalence of statins. J. Clin. Pharm. Ther. 35: 139-151.
32. Tomassini, J. E., T. Mazzone, R. B. Goldberg, J. R. Guyton, R. S. Weinstock, A. Polis, E. Jensen, and A. M. Tershakovec. 2009. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes. Metab. 11: 855-864.
33. Cross, N., M. K. Pines, and L. J. Rogers. 2004. Saliva sampling to assess cortisol levels in unrestrained common marmosets and the effect of behavioral stress. Am. J. Primatol. 62: 107-114. (Pubitemid 38319263)
34. Harchaoui, K. E., M. E. Visser, J. J. Kastelein, E. S. Stroes, and G. M. Dallinga-Thie. 2009. Triglycerides and cardiovascular risk. Curr. Cardiol. Rev. 5: 216-222.
35. Grove, D., and H. J. Pownall. 1991. Comparative specificity of plasma lecithin:cholesterol acyltransferase from ten animal species. Lipids. 26: 416-420.
36. Rousset, X., B. Vaisman, M. Amar, A. A. Sethi, and A. T. Remaley. 2009. Lecithin:cholesterol acyltransferase-from biochemistry to role in cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 16: 163-171.
37. Chang, T. Y., C. C. Chang, S. Lin, C. Yu, B. L. Li, and A. Miyazaki. 2001. Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2. Curr. Opin. Lipidol. 12: 289-296.
38. Lee, R. G., K. L. Kelley, J. K. Sawyer, R. V. Farese, Jr., J. S. Parks, and L. L. Rudel. 2004. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ. Res. 95: 998-1004. (Pubitemid 39532330)
39. Cho, K. H., J. Y. Lee, M. S. Choi, J. M. Cho, J. S. Lim, and Y. B. Park. 1998. A peptide from hog plasma that inhibits human cholesteryl ester transfer protein. Biochim. Biophys. Acta. 1391: 133-144.
40. Guyard-Dangremont, V., C. Desrumaux, P. Gambert, C. Lallemant, and L. Lagrost. 1998. Phospholipid and cholesteryl ester transfer activities in plasma from 14 vertebrate species. Relation to atherogenesis susceptibility. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 120: 517-525. (Pubitemid 28386764)
41. Oliveira, H. C., R. A. Chouinard, L. B. Agellon, C. Bruce, L. Ma, A. Walsh, J. L. Breslow, and A. R. Tall. 1996. Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive responsive elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5′-distal sequences. Cisacting sequences mapped in transgenic mice. J. Biol. Chem. 271: 31831-31838. (Pubitemid 26422203)
42. Jiang, X. C., L. B. Agellon, A. Walsh, J. L. Breslow, and A. Tall. 1992. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J. Clin. Invest. 90: 1290-1295.
43. Quinet, E. M., L. B. Agellon, P. A. Kroon, Y. L. Marcel, Y. C. Lee, M. E. Whitlock, and A. R. Tall. 1990. Atherogenic diet increases cholesteryl ester transfer protein messenger RNA levels in rabbit liver. J. Clin. Invest. 85: 357-363. (Pubitemid 20070039)
44. Gal, D., A. J. Rongione, G. A. Slovenkai, S. T. DeJesus, A. Lucas, C. D. Fields, and J. M. Isner. 1990. Atherosclerotic Yucatan microswine: an animal model with high-grade, fibrocalcific, nonfatty lesions suitable for testing catheter-based interventions. Am. Heart J. 119: 291-300. (Pubitemid 20064493)
45. Dixon, J. L., S. Shen, J. P. Vuchetich, E. Wysocka, G. Y. Sun, and M. Sturek. 2002. Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile. J. Lipid Res. 43: 1618-1629. (Pubitemid 35168276)
46. Berkhout, T. A., H. M. Simon, B. Jackson, J. Yates, N. Pearce, P. H. Groot, C. Bentzen, E. Niesor, W. D. Kerns, and K. E. Suckling. 1997. SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis. Atherosclerosis. 133: 203-212. (Pubitemid 27373497)
47. Hough, J. C., and D. R. Bassett. 1975. Cholesterol kinetic analysis in normal and cholesterol-fed rabbits; effects of saturated versus polyunsaturated fat and of cholestyramine. J. Nutr. 105: 649-659.
48. Clay, M. A., G. J. Hopkins, C. P. Ehnholm, and P. J. Barter. 1989. The rabbit as an animal model of hepatic lipase deficiency. Biochim. Biophys. Acta. 1002: 173-181. (Pubitemid 19090941)
49. Chang, S., and J. Borensztajn. 1993. Hepatic lipase function and the accumulation of beta-very-low-density lipoproteins in the plasma of cholesterol-fed rabbits. Biochem. J. 293: 745-750. (Pubitemid 23244558)
50. Uelmen, P. J., K. Oka, M. Sullivan, C. C. Chang, T. Y. Chang, and L. Chan. 1995. Tissue-specific expression and cholesterol regulation of acylcoenzyme A:cholesterol acyltransferase (ACAT) in mice. Molecular cloning of mouse ACAT cDNA, chromosomal localization, and regulation of ACAT in vivo and in vitro. J. Biol. Chem. 270: 26192-26201.
51. Downs, L. G., C. H. Bolton, S. M. Crispin, and J. M. Wills. 1993. Plasma lipoprotein lipids in five different breeds of dogs. Res. Vet. Sci. 54: 63-67.
52. Tardif, S. D., M. L. Power, C. N. Ross, J. N. Rutherford, D. G. Layne-Colon, and M. A. Paulik. 2009. Characterization of obese phenotypes in a small nonhuman primate, the common marmoset (Callithrix jacchus). Obesity (Silver Spring). 17: 1499-1505.
53. Yang, L. P., and G. M. Keating. 2009. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. Am. J. Cardiovasc. Drugs. 9: 401-409.
54. Serisier, S., F. Briand, K. Ouguerram, B. Siliart, T. Magot, and P. Nguyen. 2006. Fenofibrate lowers lipid parameters in obese dogs. J. Nutr. 136: (Suppl.): 2037-2040.
55. Srivastava, R. A., and S. He. 2010. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster. Mol. Cell. Biochem. 345: 197-206.
56. Krause, B. R., and H. M. Princen. 1998. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis. 140: 15-24. (Pubitemid 28378450)
57. Harris, W. S. 1996. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. Lipids. 31: 243-252. (Pubitemid 26094301)
58. Patel, J. V., I. Tracey, E. A. Hughes, and G. Y. Lip. 2009. Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy. Vasc. Health Risk Manag. 5: 801-810.
59. Bentzon, J. F., and E. Falk. 2010. Atherosclerotic lesions in mouse and man: is it the same disease? Curr. Opin. Lipidol. 21: 434-440.
60. Lusis, A. J. 2000. Atherosclerosis. Nature. 407: 233-241.
61. Shi, Z. S., L. Feng, X. He, A. Ishii, J. Goldstine, H. V. Vinters, and F. Vinuela. 2009. Vulnerable plaque in a Swine model of carotid atherosclerosis. AJNR Am. J. Neuroradiol. 30: 469-472.
62. Kagawa, Y., K. Hirayama, E. Uchida, Y. Izumisawa, M. Yamaguchi, T. Kotani, M. Niiyama, T. Yoshino, and H. Taniyama. 1998. Systemic atherosclerosis in dogs: histopathological and immunohistochemical studies of atherosclerotic lesions. J. Comp. Pathol. 118: 195-206. (Pubitemid 28187903)
63. Dillard, A., N. R. Matthan, and A. H. Lichtenstein. 2010. Use of hamster as a model to study diet-induced atherosclerosis. Nutr. Metab. (Lond). 7: 89.
64. Lands, W. E. M. 1960. Metabolism of glycerolipids. II. The enzymatic acylation of lysolecithin. J. Biol. Chem. 235: 2233-2237.
65. Lands, W. E., and I. Merkl. 1963. Metabolism of glycerolipids. III. Reactivity of various acyl esters of coenzyme A with alpha'- acylglycerophosphorylcholine, and positional specificities in lecithin synthesis. J. Biol. Chem. 238: 898-904.
66. Jezyk, P., and W. E. M. Lands. 1968. Specificity of acyl-CoA: phospholipid acyltransferases: solvent and temperature effects. J. Lipid Res. 9: 525-531.
67. Abd, T. T., D. J. Eapen, A. Bajpai, A. Goyal, A. Dollar, and L. Sperling. 2011. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr. Atheroscler. Rep. 13: 154-161.
68. Jinbo, T., S. Hayashi, K. Iguchi, M. Shimizu, T. Matsumoto, M. Naiki, and S. Yamamoto. 1998. Development of monkey C-reactive protein (CRP) assay methods. Vet. Immunol. Immunopathol. 61: 195-202. (Pubitemid 28206864)